The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.